The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Researchers at AACR's annual meeting said they hope the vaccine will show stronger efficacy in patients with minimal residual disease.

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.